Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 18/6/2018
SIETES contiene 92381 citas

<< anterior 21 a 40 de 77 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Lapi F, Nicotra F, Scotti L, Vannacci A, Thompson M, Pieri F, Mugelli N, Zambon A, Corrao G, Mugelli A, Rubino A. Use of antidepressant sertoninergic medications and cardiac valvulopathy: a nested case-control study in the health improvement network (THIN) database. Br J Clin Pharmacol 2012;74:536-44. [Ref.ID 93708]
22. Cita con resumen
Anónimo. New weight-loss drugs and the US obesity epidemic. Lancet 2012;380:308. [Ref.ID 93509]
23. Cita con resumen
Deltour N, Coste M, Tupinon-Mathieu I. Letter to the editor. Pharmacoepidemiol Drug Saf 2012;21:584-5. [Ref.ID 93070]
24. Cita con resumen
Brennan JM, Edwards FH, Zhao Y, O'Brien S, Booth ME, Dokholyan RS, Douglas PS, Peterson ED, DEcIDE AVR Research Team. Early anticoagulation of bioprosthetic aortic valves in older patients: results from the Society of Thoracic Surgeons Adult Cardiac Surgery National Database. J Am Coll Cardiol 2012;60:971-7. [Ref.ID 92935]
25. Cita con resumen
Anónimo. Dérivés de l'ergot de seigle: fibroses et valvulopathies. Prescrire 2012;32:361. [Ref.ID 92813]
26.Enlace a cita original
Fournier A, Zureik M. Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France. Pharmacoepidemiol Drug Saf 2012;21:343-51. [Ref.ID 92514]
27.Enlace a cita original
Krishnaswami A, Albers KB, Fross RD, Jang JJ, Berkheimer SB, Ben VCK, VanDenEeden SK. Valvular heart disease in patients exposed to pergolide: insights from the clinical presentation. Pharmacoepidemiol Drug Saf 2012;21:276-80. [Ref.ID 92466]
28.Enlace a cita original Cita con resumen
Benkimoun P. Appetite suppressant was probably responsible for 1300 deaths, study shows. BMJ 2012;344:e996. [Ref.ID 92377]
29. Cita con resumen
Anónimo. FDA panel recommends weight-loss drug phentermine/topiramate.. DIA Daily 2012:23 de febrero. [Ref.ID 92163]
30. Cita con resumen
Anónimo. Anfetaminas en España. Boletín de la Tarjeta Amarilla (Centro de Farmacovigilancia de Castilla y León) 2011:2. [Ref.ID 91964]
31. Cita con resumen
32. Cita con resumen
Wieloch M, SJälander A, Frykman V, Rosenqvist M, Eriksson N, Svensson PJ. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. Eur Heart J 2011;32:2282-9. [Ref.ID 91580]
33.Tiene citas relacionadas Cita con resumen
Braillon A. Mediator: who's to blame?. Lancet 2011;377:2003-4. [Ref.ID 91302]
34.Tiene citas relacionadas Cita con resumen
Mullard A. Mediator scandal rocks French medical community. Lancet 2011;377:890-2. [Ref.ID 90318]
35. Cita con resumen
Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, Donaldson SS, Green DM, Sklar CA, Robison LL, Leisenring WM. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2010;340:34. [Ref.ID 87668]
36. Cita con resumen
Anónimo. Benfluorex: de plus en plus de valvulopathies notifiées. Prescrire 2009;29:912. [Ref.ID 87341]
37.Tiene citas relacionadas Cita con resumen
Tricoci P, Allen JM, Kramer JM, Califf RM, Smith Jr SC. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA 2009;301:831-41. [Ref.ID 85336]
38. Cita con resumen
Charlish P. Product problems plague industry. Scrip 100 2007:S54-7. [Ref.ID 82028]
39.Tiene citas relacionadas
Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Backhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-402. [Ref.ID 81140]
40.Tiene citas relacionadas
Chaikof EL. The development of prosthetic heart valves - lessons in form and function. N Engl J Med 2007;357:1368-71. [Ref.ID 81137]
Seleccionar todas
<< anterior 21 a 40 de 77 siguiente >>